Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. The company is headquartered in Austin, Texas and currently employs 11 full-time employees. The company went IPO on 2017-06-29. The firm's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).
Dr. Brian Windsor is the President of Rein Therapeutics Inc, joining the firm since 2023.
What is the price performance of RNTX stock?
The current price of RNTX is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Rein Therapeutics Inc?
Rein Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Rein Therapeutics Inc market cap?
Rein Therapeutics Inc's current market cap is $NaN
Is Rein Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Rein Therapeutics Inc, including 2 strong buy, 4 buy, 2 hold, 0 sell, and 2 strong sell